Compare Snowflake Inc (SNOW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Snowflake Inc trades at $332.2 (market cap $116.01B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Snowflake Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap. Which is the better fit depends on your goals.
| SNOW | VRTX | |
|---|---|---|
Market Cap | $116.01B | $132.79B |
Sector | Technology | Health |
52-Week High | $334.70 | $529.65 |
52-Week Low | $121.11 | $376.62 |
Enterprise Value | $115.82B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $330.49, up 3.93% in 24 hours, approaching its 52-week high. The stock exhibits bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue growth is robust at $3.63 billion in 2025, but net losses persist at -$1.29 billion. Recent news highlights AI-driven partnerships and product launches, such as Spotfire's integration with Snowflake AI Data Cloud (Business Wire, 2026-08-05).
The outlook remains optimistic due to strong analyst buy ratings (80.77%) and a consensus price target of $302.18, though high valuation multiples (P/S 22.37) and ongoing losses pose risks. Key opportunities include AI expansion and customer growth, while competition and margin pressure are concerns. Investors should weigh growth potential against profitability challenges.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
